Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1Neoplasms 1

Interventions

apatinib 25Cisplatin 19Capecitabine 17Irinotecan 16Cyclophosphamide 16fludarabine 14Radiotherapy 12Oxaliplatin 12Drug Therapy 12camrelizumab 11Paclitaxel 11S 1 (combination) 10Docetaxel 10Carboplatin 10Fluorouracil 9Blood Specimen Collection 9Bevacizumab 9Nivolumab 8tislelizumab 7Radiation 7Pemetrexed 7Gemcitabine 7Erlotinib Hydrochloride 7Surgical Procedures, Operative 6Neoadjuvant Therapy 6Albumin-Bound Paclitaxel 6toripalimab 5anlotinib 5XELOX 5Tamoxifen 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × Megestrol × Clear all
NCT04430361 2020-06-12

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled

Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡